Searched for
SIMVASTATIN TABLETS
Fresh tailwinds emerge as government comes in again with intent: 7 pharma stocks with upside potential of up to 36%Budget 2026 underlines the government’s intent – in terms of the sectors it will focus on. Now, it is not all of a sudden that the governme...- Nifty healthcare index stocks analysts suggest buying have potential upside of more than 19%Except for a pocket in which demand for covid drugs led to sharp surge in pharma stocks, the pharma sector had been under pressure for a lo...
- After Market: DHFL, Cox & Kings plunge; 178 stocks look ready to riseDalal Street experts said that the undercurrent of the market was bearish.
- Glenmark Pharma gets USFDA nod for cholesterol-lowering drugThe approved product is a generic version of MSD International's Vytorin tablets.
- Dr Reddy's launches cholesterol lowering drug in USThe company has launched Ezetimibe and Simvastatin tablets in the strengths of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg in the...
- TRACK SENSEX, NIFTY LIVE: Who is moving my market todayIf you are reading this, chances are Sensex and Nifty are part of your daily life, and actions on Dalal Street can make or mar your day. He...
- Ten stocks in focus in Thursday morning tradeThe Indian market is expected to open higher. Here is a list of top ten stocks that are likely to be in focus today.
- Micro Labs recalls 54,096 bottles of cholesterol drug in USMicro Labs is voluntarily recalling 54,096 bottles of Simvastatin Tablets, a drug for lowering cholesterol, in the US market for failing to...
- Teva Pharmaceuticals will not be launching Atorvastatin, generic version of LipitorIsrael's Teva Pharmaceuticals will not launch atorvastatin, the generic version of Lipitor, that will help Indian cos Ranbaxy and Dr Reddy'...
- Ranbaxy to recall 3 batches of Pravastatin from UK marketRanbaxy Laboratories is recalling three batches of anticholesterol drug Pravastatin tablets from the UK market for failing to update approv...
- Ranbaxy hopeful of an early resolution to USFDA banRanbaxy said that it expects an early resolution to the issue of US Food and Drug Administration banning import of 30 generic drugs manufac...
- Flamingo enters into a pact with TevaFlamingo Pharma said it has got into an agreement with Israel's generic drug maker Teva to manufacture its Zolpidem tartrate tablets, used ...
- Ranbaxy gains double on high US salesRanbaxy Laboratories’ net profit doubled to Rs 520 crore in December 2006, spurred by US sales of its copy of Merck & Co’s cholesterol-lowe...
- Aurobindo gets Dutch board nod for SimvastatinAurobindo Pharma has received the marketing authorisation approval for a lipid-lowering agent, Simvastatin, from Medicines Evaluation Board...
- Ranbaxy wins 180-day exclusivity for simvastatinThe US Court of Appeals has upheld the 180-day exclusivity of Ranbaxy’s cholesterol-lowering drug simvastatin, reports Our Bureau. It has a...
- Win some, lose someRanbaxy Laboratories’ third quarter net profit surged nearly seven times, but its share price declined after the results were announced.
- New drug dose helps local firms regain health in USDomestic pharma majors are witnessing sharp recovery in their US business.
- Generic version of Merck's Proscar tabs from Dr. Reddy'sPharma major Dr Reddy's Laboratories announced on Saturday that it has launched the authorized generic version of Merck's Proscar tablets 5...
- Ranbaxy gets USFDA nod for SimvastatinPharma major Ranbaxy Laboratories Ltd has received approval from the USFDA for manufacturing and marketing cholesterol-lowering Simvastatin...
- Co may benefit from Zocor patent expiryWith barely two days left for patents on Merck’s ‘Zocor’ - the world’s No.2 cholestrol drug - to expire, the market seems to be betting tha...
Load More
